Cabaletta Bio, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Cabaletta Bio raised approximately $91.5M net (cash grew from $133.6M to $225.1M between year-end 2025 and June 30, 2026, per May 2026 registered direct offering). Lead product rese-cel for autoimmune diseases advanced: RESET-Myositis registrational data on track for mid-2027 with first BLA submission planned 2H27; RESET-SSc cohort (~25 patients) anticipated to initiate 4Q26; PC-free approach incorporated into RESET-MG; ElevateBio added as second CDMO alongside Lonza. Q2 2026 R&D expenses $44.4M vs. $37.6M prior year; cash runway extends into mid-2027.
Why this rating
Capital raise (~67% of market cap) extends runway and derisks near-term operations. Multiple registrational trials progressing on timeline is meaningful clinical progress. Event is significant relative to $137M company size but not transformational; execution risk remains high.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.